Here's Why Masimo (MASI) is a Strong Growth Stock

Masimo Corporation (MASI) is highlighted as a strong growth prospect, carrying a Zacks Rank #2 (Buy) and an 'A' Growth Style Score, based on Zacks Premium's methodology that integrates earnings estimate revisions with value, growth, and momentum indicators. The medical technology firm anticipates 20.5% year-over-year earnings growth for the current fiscal year, further bolstered by recent upward revisions to its FY2025 earnings estimates by analysts, positioning it as a compelling consideration for growth-oriented investors.

Analysis

Masimo Corporation (MASI) exhibits strong growth characteristics, supported by a Zacks Rank of #2 (Buy) and a top-tier 'A' for its Growth Style Score. The company's forward-looking fundamentals are compelling, with a forecasted 20.5% year-over-year earnings growth for the current fiscal year and a demonstrated history of outperforming expectations with an average earnings surprise of +13.8%. Analyst sentiment is also decidedly positive, as evidenced by four upward earnings estimate revisions for fiscal 2025 within the last 60 days, which has elevated the Zacks Consensus Estimate to $5.30 per share. Operationally, the company's performance is bifurcated: its core Healthcare segment, representing 66.6% of FY24 revenue, grew 9.4% year-over-year, while the Non-healthcare segment, at 33.4% of revenue, contracted by 9.5%. This highlights that growth is currently concentrated in its primary business line.

Key Decisions for Investors

• Given the strong quantitative signals, including a #2 Buy rank, a 20.5% earnings growth forecast, and positive analyst revisions, growth-focused investors should consider MASI as a candidate for a bullish position.
• It is crucial to monitor the performance of Masimo's two segments, as sustained momentum depends on the core Healthcare business continuing its 9.4% growth trajectory to offset the 9.5% decline in the Non-healthcare division.
• The consistent +13.8% average earnings surprise suggests a pattern of exceeding market expectations, which should be factored into valuation and considered a potential catalyst around future quarterly reports.